Compare GME & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GME | EXAS |
|---|---|---|
| Founded | 1996 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronics Distribution | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 11.0B |
| IPO Year | 2002 | N/A |
| Metric | GME | EXAS |
|---|---|---|
| Price | $22.07 | $101.51 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 20 |
| Target Price | $13.50 | ★ $77.94 |
| AVG Volume (30 Days) | 6.3M | ★ 10.8M |
| Earning Date | 12-09-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 387.37 | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $3,808,200,000.00 | $3,082,033,000.00 |
| Revenue This Year | $9.86 | $19.40 |
| Revenue Next Year | $2.83 | $13.51 |
| P/E Ratio | $25.66 | ★ N/A |
| Revenue Growth | N/A | ★ 14.47 |
| 52 Week Low | $19.93 | $38.81 |
| 52 Week High | $35.81 | $101.95 |
| Indicator | GME | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 49.71 | 89.69 |
| Support Level | $21.50 | $100.95 |
| Resistance Level | $24.00 | $101.95 |
| Average True Range (ATR) | 0.83 | 0.34 |
| MACD | 0.01 | -1.01 |
| Stochastic Oscillator | 49.46 | 64.50 |
GameStop Corp is a U.S. multichannel video game, consumer electronics, and services retailer. The company operates across Europe, Canada, Australia, and the United States. The company sells new and second-hand video game hardware, physical and digital video game software, and video game accessories, mainly through GameStop, EB Games, and Micromania stores and international e-commerce sites. The majority of sales are from the United States. The company categorizes its products in three categories: Hardware and accessories, Software, and Collectibles. The company generates the majority of its revenue from the sale of Hardware and accessories products.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.